Items Tagged ‘abraxane’

January 7th, 2016

Atezolizumab Plus Abraxane Promising New Treatment for Triple-Negative Breast Cancer

By

The investigative agent, atezolizumb, in addition to the chemotherapy agent, Abraxane (nab-paclitaxel), provides high anti-cancer responses among patients with triple-negative breast cancer. These results were recently presented at the 2015 annual San Antonio Breast Cancer Symposium. Approximately 10-20% of breast cancers are referred to as triple-negative breast cancer (TNBC). These types of cancers are both […]

View full entry

Tags: abraxane, atezolizumab, Breast Cancer, News, tnbc, Triple Negative Breast Cancer


December 23rd, 2015

Abraxane® Combo Promising in Triple Negative Breast Cancer

By

The chemotherapy combination consisting of Abraxane® (nab-paclitaxel) plus carboplatinum (carbo) improves outcomes compared with Abraxane plus Gemzar (gemcitabine) for triple negative breast cancer. These results were presented at the 2015 annual San Antonio Breast Cancer Symposium (SABCS). Approximately 10-20% of breast cancers are referred to as triple negative breast cancer (TNBC). These types of cancers […]

View full entry

Tags: abraxane, Breast Cancer, gemzar, News, tnbc, Triple Negative Breast Cancer


December 11th, 2014

German Study Demonstrate Significant Pathological Complete Response for Abraxane® in Early Stage Breast Cancer

By

Doctors from Germany reported the results of a clinical trial at the San Antonio Breast Cancer Symposium (SABCS) demonstrating that Abraxane®(nab-paclitaxel) is superior to conventional solvent-based paclitaxel for the treatment of women with early high-risk breast cancer. Nab-paclitaxel encapsulates paclitaxel in near-nano-sized albumin, protein shells. This takes advantage of the natural transport properties of albumin […]

View full entry

Tags: abraxane, Breast Cancer, News, palictaxel, Stages II-III Breast Cancer


July 1st, 2014

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy

By

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated patients with metastatic pancreatic cancer was presented recently at the annual American Society of Clinical Oncology meeting in Chicago.1  Results of the study were initially reported in the New England Journal of Medicine.2 Pancreatic cancer […]

View full entry

Tags: abraxane, gemzar, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer